OptiPharm Co

OptiPharm Co EBIT Margin

The EBIT Margin (Operating Margin) of OptiPharm Co (153710.KQ) as of Nov 2, 2026 is -12.49 %. In the previous year, EBIT Margin (Operating Margin) was -15.14 % — a change of -17.55% (higher).

EBIT Margin

-12.49 %

YoY

-17.55%

Last updated:

EBIT Margin (Operating Margin) of OptiPharm Co is 2024 -12.49 % . EBIT Margin (Operating Margin) of OptiPharm Co was 2023 -15.14 % . It decreases by -17.55% higher compared to the previous year.

OptiPharm Co's operating (EBIT) margin stands at -12.5%, up from -26.5% several years earlier.

The OptiPharm Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
-11.77 KRW
Jan 1, 2018
-4.99 KRW
Jan 1, 2019
-8.72 KRW
Jan 1, 2020
-26.47 KRW
Jan 1, 2021
-31.59 KRW
Jan 1, 2022
-21.10 KRW
Jan 1, 2023
-15.14 KRW
Jan 1, 2024
-12.49 KRW
The OptiPharm Co EBIT Margin history
YEAREBIT MarginYoY
-12.49 %-17.55%
-15.14 %-28.21%
-21.10 %-33.23%
-31.59 %+19.34%
-26.47 %+203.45%
-8.72 %+74.85%
-4.99 %-57.62%
-11.77 %-8,535.91%
0.14 %-100.85%
-16.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiPharm Co Stock analysis

What does OptiPharm Co do? OptiPharm Co Ltd generates revenue through its Sale Business segment, which provides livestock disease appraisal services, distributes animal drugs, and manufactures and sells feed additives. The New Business segment develops heterologous organisms, VLP vaccines, and human diagnostic kits, including heterologous skin, xenogeneic islets, and xenogeneic corneal products, as well as VLP-based animal combined vaccines and HPV vaccines for humans. Human diagnostic kits target breast and cervical cancer reagents. Products are distributed domestically and internationally, serving both local and overseas markets. The company's primary customers are domestic and international buyers of pharmaceuticals, livestock health products, and diagnostic solutions. The Sale Business segment caters to agricultural and veterinary sectors, while the New Business segment serves healthcare providers and diagnostic laboratories. Revenue streams include product sales from both segments, with a focus on high-demand medical and animal health solutions. OptiPharm Co Ltd's business model relies on manufacturing and wholesaling pharmaceuticals, with the Sale Business segment emphasizing livestock health services and animal drug distribution, and the New Business segment focusing on innovative medical technologies. The firm's product portfolio spans from feed additives to advanced diagnostic kits, targeting both domestic and global markets for sustainable growth. OptiPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiPharm Co stock

EBIT Margin (Operating Margin) of OptiPharm Co is -12.49 % in 2024.

EBIT Margin (Operating Margin) of OptiPharm Co changed from -15.14 % to -12.49 %, representing a -17.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) OptiPharm Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s OptiPharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — OptiPharm Co

All Key Metrics — OptiPharm Co